Patients
WEST
This prospective, randomized trial was conducted at three centers: West China Hospital of Sichuan University, Affiliated Hospital of Southwest Medical University, and Dazhou Central Hospital. The inclusion criteria were as follow: ≥60 years of age, frail (frailty score ≥ 2), newly diagnosed MM meeting the IMWGAs ixazomib was more expensive than bortezomib in China, many patients who met the eligibility criteria refused to enroll in the clinical trial because of financial and health insurance concerns. Overall, 42 patients were included in this study from July 2020 to June 2022. Among them, 36 patients (19 in the ixazomib+cyclophosphamide+Dexamethasone [ICd] group and 17 in the ixazomib+dexamethasone [Id] group) had received at least two cycles of therapy, and they were further assessed. The last day of the observation period was June 30, 2022, and the study is ongoing.The study was approved by the Ethics Committee of West China Hospital of Sichuan University and review boards at all institutions that participated in this study. The research was performed in compliance with the the Guidelines for Good Clinical Practice, the Guidelines of the International Conference on Harmonization, and the Declaration of Helsinki. Informed consent was obtained from all the participants before the initiation of the study.